Welcome to our dedicated page for Check Cap news (Ticker: CHEK), a resource for investors and traders seeking the latest updates and insights on Check Cap stock.
Check-Cap Ltd. (CHEK) is a clinical-stage innovator in non-invasive screening, developing the C-Scan® ingestible capsule for colorectal cancer detection. This page provides investors and medical professionals with essential updates on the company's advancements in patient-friendly diagnostic technology.
Access authoritative updates on clinical trial progress, regulatory milestones, and strategic partnerships. Our curated news collection focuses on developments directly impacting Check-Cap's position in preventive healthcare solutions, including technological refinements to its low-dose X-ray imaging system.
Key updates cover FDA communications, trial phase results, and collaborations with healthcare institutions. All content is verified through primary sources to ensure accuracy for investment and research decisions.
Bookmark this page for streamlined access to Check-Cap's evolving role in transforming colorectal screening through preparation-free technology. Monitor critical developments in medical imaging innovation and diagnostic accessibility.
Rhea-AI Summary
Nobul AI Corp. and Check-Cap have agreed to a business combination to form a North American technology company focusing on an AI-driven fintech marketplace. The combined company, if approved, will be listed on NASDAQ and TSX, with Nobul's executive team leading the merged entity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.7%
Tags
-
Rhea-AI Summary
Symetryx Corporation (Symetryx) (NASDAQ: CHEK) successfully elected all director nominees proposed by Symetryx at the Annual General Meeting, with CHEK shareholders voting overwhelmingly against the proposed merger with Keystone Dental. President Barry R. Shiff expressed gratitude for the support and emphasized the potential upside at CHEK. Check-Cap, based in Isfiya, Israel, developed the breakthrough C-Scan technology to prevent colorectal cancer, receiving regulatory clearances in Europe and FDA Breakthrough Device Designation in 2021.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.7%
Tags
-
Rhea-AI Summary
Symetryx (NASDAQ: CHEK) recommends voting against the Keystone Dental merger and for their qualified independent board nominees. The vote deadline is 11:59 pm EST on December 14th, 2023. Symetryx continues to urge Check-Cap Ltd. shareholders to vote against the Keystone Dental and for the Symetryx slate of highly qualified and independent director nominees. A potential conflict of interest between Uri Geiger, the Chairman of Keystone Dental, and Yuval Yanai, a Check-Cap director, has been revealed during a court hearing in the Haifa Israel Economic District Court.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Symetryx Corporation (NASDAQ: CHEK) continues to urge Check-Cap Ltd. shareholders to vote against the Keystone Dental and for the Symetryx slate of director nominees. Keystone Dental received a deficiency letter from the FDA regarding its Paltop Short Implants, potentially harming its business and negatively impacting shareholders' investment. Hundreds of adverse events have been reported by Keystone Dental to the FDA, which may drive clinicians to choose other brands. Symetryx is urging shareholders to reject the Keystone transaction and support the Symetryx Board nominees to realize the full value of their investment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
-
Rhea-AI Summary
Symetryx Corporation (SYMX) continues to urge Check-Cap Ltd. (CHEK) shareholders to vote against the Keystone Dental transaction and for the Symetryx slate of director nominees. The company believes that the transaction with Keystone Dental does not provide the maximum value for shareholders and that only with a new, independent Board, shareholders will have the best opportunity to realize the full value of their investment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.77%
Tags
-
News
Rhea-AI Summary
Symetryx Corporation (Symetryx) has issued an open letter to shareholders, urging them to vote against the proposed transaction with Keystone Dental and to support Symetryx's five director nominees. Symetryx raises concerns about the unrealistic valuation of Keystone Dental and the troubling cash burn by Check-Cap Board & Management. Symetryx fears that the proposed merger would cause an alarmingly high level of dilution to the shareholders. The Proxy Statement for the Check-Cap Annual General Meeting is scheduled for December 18th, 2023, and Symetryx recommends shareholders to vote against the Keystone Merger Proposal.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.87%
Tags
Rhea-AI Summary
Check-Cap Ltd. (NASDAQ: CHEK) shareholders will vote on a proposed Business Combination Agreement with Keystone Dental at the Annual General Meeting on Monday, December 18th. Keystone Dental will become the majority holders of the combined company, creating a public company focused on advancing commercial execution and market development of dental implant technologies. The company will trade on the NASDAQ under the symbol 'KSD'. Financial results for the third quarter and nine months ended September 30, 2023, show a decrease in research and development activities, an increase in general and administrative expenses, and a net loss of $2.6 million for the third quarter and $13.9 million for the nine months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.76%
Tags
-
Rhea-AI Summary
Symetryx opposes Check-Cap/Keystone merger
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.98%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.57%
Tags
Rhea-AI Summary
Symetryx Corporation has increased its non-binding proposal to acquire Check-Cap LTD to $4.60 per share in cash. Symetryx urges the Check Board to engage in communications and allow due diligence. The proposal is contingent upon various conditions and may create substantial value for Check shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.22%
Tags
Check Cap